Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT03939182
- Phase
- PHASE1
- Status
- Completed
Conditions
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Abexinostat — DRUGTwo doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
- Ibrutinib — DRUGIbrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
Study Details
The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.
Key Dates
- Start date
- May 29, 2019
- Status verified
- Apr 2025
- Primary completion
- Apr 22, 2025
- Completion
- Apr 22, 2025
Study Design
- Enrollment
- 15 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Abexinostat and IbrutinibThe investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
Primary Outcome Measure
the MTD of abexinostat when combined with ibrutinib [ Time Frame: 1 year ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | - |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York | 11570 | - |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | - |
Find similar trials in Basking Ridge, NJ
By research site
Memorial Sloan Kettering Basking Ridge· Basking Ridge, NJMemorial Sloan Kettering Monmouth· Middletown, NJMemorial Sloan Kettering Commack· Commack, NYMemorial Sloan Kettering Westchester· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NYMemorial Sloan Kettering Rockville Centre· Rockville Centre, NY
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaPHASE1/PHASE2 · Recruiting · New York Medical College · Valhalla, New York